Friday 6 November 2026
Export JAZZ’s income statement to Excel — free account
Jazz Pharmaceuticals PLC
JAZZ Healthcare Biotechnology
Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- −280.5%
- Free cash flow
- −60.4%
- Total debt
- +3.88%
Quarter to September 2026, against a year earlier
235.28
7.96
+3.50%
Follow JAZZ
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
5 | 6 | 7 | 7 |
| (8.47%) | 0.68% | 22.11% | 5.05% | ||
| (3.01%) | 0.25% | 8.54% | 1.76% | ||
ROIC |
(3.72%) | (0.34%) | 8.06% | 3.86% | |
Return on Tangible Assets |
(16.77%) | 1.16% | 48.26% | 8.94% | |
Average Days of Receivables |
71.05 | 68.77 | 69.88 | 67.59 | |
Free Cash Flow per Share |
5.18 | 5.07 | 22.41 | 10.27 | |
Free Cash Flow |
316.14 | 313.74 | 1,416.54 | 664.54 | |
Capital Expenditures |
(1,039.64) | (1,020.44) | (244.54) | (1,027.94) | |
| Other line items | |||||
Cash ROIC |
2.61% | 2.46% | 12.48% | 5.27% | |
Accounts Receivable Turnover |
5.52 | 5.96 | 5.77 | 5.76 | |
Accounts Payable Turnover |
5.03 | 5.44 | 4.89 | 1.93 | |
Inventory Turnover |
1.12 | 1.15 | 1.12 | 1.10 | |
Average Days of Payables |
88.55 | 68.51 | 88.01 | 269.74 | |
Days of Inventory on Hand |
302.42 | 299.72 | 303.43 | 322.02 | |
Tax Rate |
(0.43) | (1.14) | 0.29 | (0.21) | |
Research and Development Expense of Revenue |
18.34% | 17.98% | 17.73% | 17.58% | |
Selling, General and Administrative Expense of Revenue |
42.40% | 37.13% | 36.48% | 32.98% | |
Share Based Compensation of Revenue |
6.82% | 6.71% | 6.67% | 6.27% | |
Interest Coverage |
(2.21) | (0.21) | 5.25 | 2.54 | |
Operating CF/Net income |
(3.81) | 45.30 | 1.77 | 8.22 | |
Depreciation/Fixed assets |
3.48 | 3.51 | 3.39 | 3.20 | |
Capex/Depreciation |
(1.49) | (1.43) | (0.34) | (1.43) | |
Revenue per Share |
69.98 | 71.71 | 72.81 | 72.92 | |
Operating CF per Share |
22.23 | 21.55 | 26.28 | 26.16 | |
Capex per Share |
(17.05) | (16.49) | (3.87) | (15.89) | |
Capex to Sales |
0.24 | 0.23 | 0.05 | 0.22 |
Columns are period end dates · fundamentals updated 5 Nov 2026